Atossa to Present at the Sidoti Small-Cap Investor Conference

Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) will present at the Sidoti Small-Cap Investor Conference on June 12-13, 2024. Dr. Steven Quay, CEO, will deliver the presentation on June 13 at 9:15 am ET. Atossa, a clinical-stage biopharma company, focuses on developing innovative oncology treatments, particularly for breast cancer. Interested parties can register to view the live webcast through the event's website. A recording will be available afterward on Atossa's investor relations page.

Positive

• Atossa will gain exposure at the Sidoti Small-Cap Investor Conference, potentially attracting new investors.
• The CEO's presentation can highlight Atossa's innovative oncology treatments, enhancing its reputation.
• Availability of the presentation recording on the investor relations page ensures continued investor engagement.

Negative

• No new clinical data or financial results were reported, which may disappoint investors seeking updates.
• The announcement does not mention any new partnerships or significant business developments.

SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

To register and view a live webcast of the presentation, please visit the event's website at: https://sidoti.zoom.us/webinar/register/WN_MB9PZN5rTjeg5vMpcE82Gg

Following the conference, a recording of the webcast will be made available on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com/

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com

FAQ

What is the date of Atossa Therapeutics' presentation at the Sidoti Small-Cap Investor Conference?

Atossa Therapeutics will present on June 13, 2024, at 9:15 am ET.

How can I view Atossa Therapeutics' presentation at the Sidoti Small-Cap Investor Conference?

You can register and view the live webcast through the event's website.

What focus does Atossa Therapeutics have in its clinical-stage biopharma development?

Atossa Therapeutics focuses on innovative oncology treatments, particularly for breast cancer.

Will the Sidoti Small-Cap Investor Conference presentation be available after the event?

Yes, a recording of the webcast will be available on Atossa's investor relations page.